344 related articles for article (PubMed ID: 36966267)
1. Antibody-Drug Conjugate Revolution in Breast Cancer: The Road Ahead.
Grinda T; Rassy E; Pistilli B
Curr Treat Options Oncol; 2023 May; 24(5):442-465. PubMed ID: 36966267
[TBL] [Abstract][Full Text] [Related]
2. Antibody-Drug Conjugates in Triple Negative Breast Cancer.
Keskinkilic M; Sacks R
Clin Breast Cancer; 2024 Apr; 24(3):163-174. PubMed ID: 38341370
[TBL] [Abstract][Full Text] [Related]
3. Sacituzumab govitecan and trastuzumab deruxtecan: two new antibody-drug conjugates in the breast cancer treatment landscape.
Adams E; Wildiers H; Neven P; Punie K
ESMO Open; 2021 Aug; 6(4):100204. PubMed ID: 34225076
[TBL] [Abstract][Full Text] [Related]
4. Sequencing Antibody Drug Conjugates in Breast Cancer: Exploring Future Roles.
Fenton MA; Tarantino P; Graff SL
Curr Oncol; 2023 Nov; 30(12):10211-10223. PubMed ID: 38132377
[TBL] [Abstract][Full Text] [Related]
5. Antibody-drug conjugates in metastatic triple negative breast cancer: a spotlight on sacituzumab govitecan, ladiratuzumab vedotin, and trastuzumab deruxtecan.
McGuinness JE; Kalinsky K
Expert Opin Biol Ther; 2021 Jul; 21(7):903-913. PubMed ID: 33089726
[TBL] [Abstract][Full Text] [Related]
6. [Chinese expert consensus of antibody-drug conjugate toxicity management for breast cancer].
;
Zhonghua Zhong Liu Za Zhi; 2022 Sep; 44(9):913-927. PubMed ID: 36164692
[TBL] [Abstract][Full Text] [Related]
7. Sacituzumab govitecan, a novel, third-generation, antibody-drug conjugate (ADC) for cancer therapy.
Goldenberg DM; Sharkey RM
Expert Opin Biol Ther; 2020 Aug; 20(8):871-885. PubMed ID: 32301634
[TBL] [Abstract][Full Text] [Related]
8. Breaking barriers in triple negative breast cancer (TNBC) - Unleashing the power of antibody-drug conjugates (ADCs).
Dri A; Arpino G; Bianchini G; Curigliano G; Danesi R; De Laurentiis M; Del Mastro L; Fabi A; Generali D; Gennari A; Guarneri V; Santini D; Simoncini E; Zamagni C; Puglisi F
Cancer Treat Rev; 2024 Feb; 123():102672. PubMed ID: 38118302
[TBL] [Abstract][Full Text] [Related]
9. Antibody-Drug Conjugates in Breast Cancer: Ascent to Destiny and Beyond-A 2023 Review.
Xiao T; Ali S; Mata DGMM; Lohmann AE; Blanchette PS
Curr Oncol; 2023 Jul; 30(7):6447-6461. PubMed ID: 37504334
[TBL] [Abstract][Full Text] [Related]
10. Antibody-drug conjugates targeting TROP-2: Clinical development in metastatic breast cancer.
Shastry M; Jacob S; Rugo HS; Hamilton E
Breast; 2022 Dec; 66():169-177. PubMed ID: 36302269
[TBL] [Abstract][Full Text] [Related]
11. Sacituzumab govitecan: antibody-drug conjugate in triple-negative breast cancer and other solid tumors.
Fenn KM; Kalinsky K
Drugs Today (Barc); 2019 Sep; 55(9):575-585. PubMed ID: 31584574
[TBL] [Abstract][Full Text] [Related]
12. Sacituzumab Govitecan-hziy in Refractory Metastatic Triple-Negative Breast Cancer.
Bardia A; Mayer IA; Vahdat LT; Tolaney SM; Isakoff SJ; Diamond JR; O'Shaughnessy J; Moroose RL; Santin AD; Abramson VG; Shah NC; Rugo HS; Goldenberg DM; Sweidan AM; Iannone R; Washkowitz S; Sharkey RM; Wegener WA; Kalinsky K
N Engl J Med; 2019 Feb; 380(8):741-751. PubMed ID: 30786188
[TBL] [Abstract][Full Text] [Related]
13. Sacituzumab Govitecan in Metastatic Triple-Negative Breast Cancer.
Bardia A; Hurvitz SA; Tolaney SM; Loirat D; Punie K; Oliveira M; Brufsky A; Sardesai SD; Kalinsky K; Zelnak AB; Weaver R; Traina T; Dalenc F; Aftimos P; Lynce F; Diab S; Cortés J; O'Shaughnessy J; Diéras V; Ferrario C; Schmid P; Carey LA; Gianni L; Piccart MJ; Loibl S; Goldenberg DM; Hong Q; Olivo MS; Itri LM; Rugo HS;
N Engl J Med; 2021 Apr; 384(16):1529-1541. PubMed ID: 33882206
[TBL] [Abstract][Full Text] [Related]
14. Sacituzumab govitecan: past, present and future of a new antibody-drug conjugate and future horizon.
Furlanetto J; Marmé F; Loibl S
Future Oncol; 2022 Sep; 18(28):3199-3215. PubMed ID: 36069628
[TBL] [Abstract][Full Text] [Related]
15. Next-generation antibody-drug conjugates for breast cancer: Moving beyond HER2 and TROP2.
Schlam I; Moges R; Morganti S; Tolaney SM; Tarantino P
Crit Rev Oncol Hematol; 2023 Oct; 190():104090. PubMed ID: 37562695
[TBL] [Abstract][Full Text] [Related]
16. Sacituzumab govitecan: an antibody-drug conjugate.
Sahota S; Vahdat LT
Expert Opin Biol Ther; 2017 Aug; 17(8):1027-1031. PubMed ID: 28503956
[TBL] [Abstract][Full Text] [Related]
17. Unveiling the antibody-drug conjugates portfolio in battling Triple-negative breast cancer: Therapeutic trends and Future horizon.
Khadela A; Soni S; Shah AC; Pandya AJ; Megha K; Kothari N; Cb A
Med Oncol; 2022 Dec; 40(1):25. PubMed ID: 36456774
[TBL] [Abstract][Full Text] [Related]
18. A plain language summary of the TROPiCS-02 study in patients with breast cancer (HR-positive/HER2-negative).
Rugo HS; Bardia A; Marmé F; Cortés J; Schmid P; Spears PA; Tolaney SM
Future Oncol; 2024 Apr; 20(11):635-651. PubMed ID: 38270051
[TBL] [Abstract][Full Text] [Related]
19. Sacituzumab Govitecan: First Approval.
Syed YY
Drugs; 2020 Jul; 80(10):1019-1025. PubMed ID: 32529410
[TBL] [Abstract][Full Text] [Related]
20. Novel HER2-Targeting Antibody-Drug Conjugates of Trastuzumab Beyond T-DM1 in Breast Cancer: Trastuzumab Deruxtecan(DS-8201a) and (Vic-)Trastuzumab Duocarmazine (SYD985).
Xu Z; Guo D; Jiang Z; Tong R; Jiang P; Bai L; Chen L; Zhu Y; Guo C; Shi J; Yu D
Eur J Med Chem; 2019 Dec; 183():111682. PubMed ID: 31563805
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
